Pentasa
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
: There is increasing interest in using higher dosages of mesalazine for the treatment of inflammatory bowel disease; however…
Summary: The safety and efficacy of mesalamine enemas were determined in a dose‐ranging study enrolling 287 patients with…
Background: The incidence of the side‐effects of 5‐aminosalicylic acid (5‐ASA) in clinical practice is not known.
Objective: To investigate a possible dose–effect relationship with two dosages of oral slow-release mesalazine in patients with…
OBJECTIVE
To investigate a possible dose-effect relationship with two dosages of oral slow-release mesalazine in patients with…
Release of 5‐ASA from a sustained release formulation (Pentasa®, Ferring A/S, Copenhagen, Denmark) was monitored with plasma…
A double-blind, placebo-controlled trial of a slow-release preparation of 5-amino-salicylic acid (Pentasa) has been performed in…
The response to 5-aminosalicylic acid (5-ASA) in mild and moderately active Crohn's disease localized in the small bowel was…
The influence of intestinal transit time on the release of 5-aminosalicylic acid (5-ASA) from a peroral, slow-release preparation…